{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:36:56Z","timestamp":1793320616438,"version":"4.5.0"},"reference-count":29,"publisher":"Bioscientifica","issue":"2","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A Japanese phase 2 trial of encorafenib plus binimetinib met the primary endpoint of the centrally assessed objective response rate in patients with unresectable BRAF V600E-mutated thyroid cancer. Consequently, encorafenib plus binimetinib has been approved in Japan. We present the health-related quality of life (HR-QoL) outcomes from the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The multicenter, open-label, uncontrolled phase 2 trial enrolled patients with unresectable locally advanced or metastatic BRAF V600E-mutated thyroid cancer. HR-QoL score, one of the secondary endpoints, was assessed using the EORTC QLQ-C30 and QLQ-THY34 at baseline and during follow-up. The minimal important change (MIC) threshold was set at 10 points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We enrolled 22 patients with BRAF V600E-mutated thyroid cancer. The median follow-up was 11.5 months. Completion rates for the questionnaires were 100% (22 of 22 patients) at baseline and 68% (15 of 22) at week 20. Until week 20, changes from baseline were below MIC at most time points in 29 of all 32 domains in QLQ-C30 and QLQ-THY34. In the other 3 domains, patients showed tendencies toward improvement (social support and appetite loss) or deterioration (joint pain) for consecutive time points. Patients with anaplastic thyroid cancer showed tendencies toward improvement for swallowing, restlessness, body image, and discomfort in the head and neck, from the first assessment after the initial treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination therapy of encorafenib plus binimetinib for unresectable BRAF V600E-mutated thyroid cancer was associated with generally maintained HR-QoL. Considering the efficacy and safety data from the trial, the regimen may provide clinical benefits while maintaining HR-QoL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-25-0273","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:06:53Z","timestamp":1774526813000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":1,"title":["Health-related quality of life with encorafenib plus binimetinib for\n                    <i>BRAF<\/i>\n                    V600E thyroid cancer"],"prefix":"10.1530","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8021-6116","authenticated-orcid":true,"given":"Naomi","family":"Kiyota","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9035-3106","authenticated-orcid":true,"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Imai","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Tamura","sequence":"additional","affiliation":[{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[{"name":"8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Ito","sequence":"additional","affiliation":[{"name":"9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hirashima","sequence":"additional","affiliation":[{"name":"10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Ueno","sequence":"additional","affiliation":[{"name":"10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-0706","authenticated-orcid":true,"given":"Iwao","family":"Sugitani","sequence":"additional","affiliation":[{"name":"11"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2026070714011004100_bib1","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/biomedicines12061286","article-title":"Recent trends and potential of radiotherapy in the treatment of anaplastic thyroid cancer","volume":"12","author":"Sekihara","year":"2024","journal-title":"Biomedicines"},{"key":"2026070714011004100_bib2","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-24-0287","article-title":"Anticancer drug therapy for anaplastic thyroid cancer","volume":"14","author":"Kiyota","year":"2025","journal-title":"Eur Thyroid J"},{"key":"2026070714011004100_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1272\/jnms.2018_85-3","article-title":"Management of anaplastic thyroid carcinoma: the fruits from the ATC research consortium of Japan","volume":"85","author":"Sugitani","year":"2018","journal-title":"J Nippon Med Sch"},{"key":"2026070714011004100_bib4","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/clinem\/dgae271","article-title":"Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan","volume":"109","author":"Toda","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714011004100_bib5","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"2026070714011004100_bib6","first-page":"1184","article-title":"Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","journal-title":"Thyroid"},{"key":"2026070714011004100_bib7","first-page":"467","article-title":"A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan","volume":"34","author":"Tahara","year":"2024","journal-title":"Thyroid"},{"key":"2026070714011004100_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/0284186X.2012.741326","article-title":"Health-related quality of life and disease specific symptoms in long-term thyroid cancer survivors: a study from the population-based PROFILES registry","volume":"52","author":"Husson","year":"2013","journal-title":"Acta Oncologica"},{"key":"2026070714011004100_bib9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00259-015-3022-9","article-title":"Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme","volume":"42","author":"Gamper","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"2026070714011004100_bib10","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00595-022-02494-8","article-title":"Surgical resection of the primary tumor prevents an undesirable locoregional condition and improves the quality of life in patients with anaplastic thyroid cancer","volume":"52","author":"Kanai","year":"2022","journal-title":"Surg Today"},{"key":"2026070714011004100_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1089\/thy.2020.0276","article-title":"Safety and quality-of-life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer","volume":"31","author":"Giani","year":"2021","journal-title":"Thyroid"},{"key":"2026070714011004100_bib12","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1089\/thy.2023.0553","article-title":"A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer","volume":"34","author":"Tahara","year":"2024","journal-title":"Thyroid"},{"key":"2026070714011004100_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000359","article-title":"Management of recurrent or metastatic thyroid cancer","volume":"3","author":"Tahara","year":"2018","journal-title":"ESMO Open"},{"key":"2026070714011004100_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070714011004100_bib15","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","article-title":"A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer","volume":"29","author":"Leboulleux","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026070714011004100_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1530\/ERC-16-0530","article-title":"The EORTC module for quality of life in patients with thyroid cancer: phase III","volume":"24","author":"Singer","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"2026070714011004100_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","article-title":"Recist 1.1 \u2013 standardisation and disease-specific adaptations: perspectives from the RECIST working group","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026070714011004100_bib18","volume-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001","edition":"3rd edn"},{"key":"2026070714011004100_bib19","first-page":"1078","article-title":"International phase IV field study for the reliability and validity of the European Organisation for Research and treatment of cancer thyroid cancer module EORTC QLQ-THY34","volume":"33","author":"Singer","year":"2023","journal-title":"Thyroid"},{"key":"2026070714011004100_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"2026070714011004100_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types","volume":"188","author":"Musoro","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026070714011004100_bib22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2021.04.028","article-title":"Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: results from a multicentre, open-label, randomised, phase III study (COLUMBUS)","volume":"152","author":"Gogas","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026070714011004100_bib23","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1200\/JCO.21.02659","article-title":"COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026070714011004100_bib24","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s10147-025-02693-6","article-title":"Post-marketing surveillance of encorafenib in combination with binimetinib in Japanese patients with BRAF-mutant melanoma","volume":"30","author":"Yamazaki","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"2026070714011004100_bib25","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026070714011004100_bib26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"2026070714011004100_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070714011004100_bib28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","article-title":"Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma","volume":"7","author":"Welsh","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"2026070714011004100_bib29","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/15\/2\/ETJ-25-0273.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/15\/2\/ETJ-25-0273.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0273\/503429\/etj-25-0273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0273\/503429\/etj-25-0273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:01:17Z","timestamp":1783447277000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/15\/2\/ETJ250273\/75647\/Health-related-quality-of-life-with-encorafenib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0273","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"article-number":"ETJ250273"}}